Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?

被引:62
|
作者
Alshamrani, Ali A. [1 ]
机构
[1] King Saud Univ, Dept Pharmacol & Toxicol, Coll Pharm, Riyadh, Saudi Arabia
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
microRNA; ovarian cancer; proliferation; biomarkers; chemoresistance; diagnosis; prognosis; target genes; GLUTATHIONE-S-TRANSFERASE; SUPPRESSES TUMOR-GROWTH; PROMOTES CELL-GROWTH; CISPLATIN RESISTANCE; DOWN-REGULATION; MIR-200; FAMILY; UP-REGULATION; ENHANCES CHEMOSENSITIVITY; MULTIDRUG-RESISTANCE; INHIBITS METASTASIS;
D O I
10.3389/fonc.2020.01084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is one of the top gynecological malignancies that cause deaths among females in the United States. At the molecular level, significant progress has been made in our understanding of ovarian cancer development and progression. MicroRNAs (miRNAs) are short, single-stranded, highly conserved non-coding RNA molecules (19-25 nucleotides) that negatively regulate target genes post-transcriptionally. Over the last two decades, mounting evidence has demonstrated the aberrant expression of miRNAs in different human malignancies, including ovarian carcinomas. Deregulated miRNAs can have profound impacts on various cancer hallmarks by repressing tumor suppressor genes. This review will discuss up-to-date knowledge of how the aberrant expression of miRNAs and their targeted genes drives ovarian cancer initiation, proliferation, survival, and resistance to chemotherapies. Understanding the mechanisms by which these miRNAs affect these hallmarks should allow the development of novel therapeutic strategies to treat these lethal malignancies.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Heart surgery over two decades: what we have learned about results and changing risks
    Tajdini, Masih
    Behnoush, Amir Hossein
    Pashang, Mina
    Jameie, Mana
    Khalaji, Amirmohammad
    Sadeghian, Saeed
    Vasheghani-Farahani, Ali
    Poorhosseini, Hamidreza
    Masoudkabir, Farzad
    Hosseini, Kaveh
    Davoodi, Saeed
    Sahebjam, Mohammad
    Barkhordari, Khosro
    Ashraf, Haleh
    Shafiei, Akbar
    Karimi, Abbasali
    Ahmadi Tafti, Seyed Hossein
    Mansourian, Soheil
    Shirzad, Mahmood
    Bagheri, Jamshid
    Jalali, Arash
    Abbasi, Kiomars
    Zoroufian, Arezou
    Hosseinsabet, Ali
    Davarpasand, Tahereh
    Mohseni-Badalabadi, Reza
    Hali, Reza
    Mehrabanian, Mohammadjavad
    Dehghani Firoozabadi, Mehdi
    Nooralishahi, Behrang
    Mortazavi, Seyedeh Hamideh
    Lotfi-Tokaldany, Masoumeh
    Rostami, Elham
    Karimi, Mahdieh
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01) : 195
  • [42] Aortic graft infection - What have we learned during the last decades ?
    Oderich, GS
    Panneton, JM
    ACTA CHIRURGICA BELGICA, 2002, 102 (01) : 7 - 13
  • [43] Three decades of transplantation for chronic myeloid leukemia: what have we learned?
    Pavlu, Jiri
    Szydlo, Richard M.
    Goldman, John M.
    Apperley, Jane F.
    BLOOD, 2011, 117 (03) : 755 - 763
  • [44] The relationship between crime and drugs: What we have learned in recent decades
    Deitch, D
    Koutsenok, I
    Ruiz, A
    JOURNAL OF PSYCHOACTIVE DRUGS, 2000, 32 (04) : 391 - 397
  • [45] Schema theory - and what we have learned over the past four decades
    Wulf, Gabriele
    JOURNAL OF SPORT & EXERCISE PSYCHOLOGY, 2016, 38 : S14 - S14
  • [46] Surgical Therapy for Macular Edema: What We Have Learned through the Decades
    Bae, Jeong Hun
    Al-khersan, Hasenin
    Yannuzzi, Nicolas A.
    Hasanreisoglu, Murat
    Androudi, Sofia
    Albini, Thomas A.
    Quan Dong Nguyen
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (08) : 1242 - 1250
  • [47] Lymphopenia in Esophageal Cancer: What Have We Learned?
    Wang, Jia-Lin
    Ma, Rong
    Kong, Wei
    Zhao, Ren
    Wang, Yan-Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] DNA Sequencing of Cancer: What Have We Learned?
    Chmielecki, Juliann
    Meyerson, Matthew
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 63 - 79
  • [49] Two decades with omalizumab: what we still have to learn
    Incorvaia, Cristoforo
    Mauro, Marina
    Makri, Elena
    Leo, Gualtiero
    Ridolo, Erminia
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 135 - 142
  • [50] Locally Advanced Rectal Cancer: What We Learned in the Last Two Decades and the Future Perspectives
    Vivek Srivastava
    Aakansha Giri Goswami
    Somprakas Basu
    Vijay Kumar Shukla
    Journal of Gastrointestinal Cancer, 2023, 54 : 188 - 203